Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 19.00
Low: 17.85
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing, supply & profit sharing agreement

1 Nov 2017 07:00

RNS Number : 1441V
OptiBiotix Health PLC
01 November 2017
 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Manufacturing, supply and profit sharing agreement with Knighton Foods

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a manufacturing and supply agreement with Knighton Foods, ("Knighton"). The agreement grants Knighton an exclusive licence to manufacture and supply OptiBiotix's SlimBiome® weight management technology in the United Kingdom, in return for 50% of the profit, with an agreed cost of manufacture and minimum sales price per kilogramme.

 

Knighton, a wholly owned subsidiary of Premier Foods plc, is a leading producer of a wide range of high quality, value adding, functional powdered foods, specialist ingredients and finished products, to some of the countries major supermarkets, high street coffee houses, and best-known household brands. Knighton's advanced powder technology was key to developing an improved version of SlimBiome®, providing enhanced solubility and better product presentation, greatly improving flavour and mouthfeel.

 

SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be supplied by Knighton as a specialised functional ingredient, into a wide range of finished products for use in the retail, vending, and ingredients sectors. Knighton will use their best endeavours to promote and expand the supply of SlimBiome®, bringing it to the attention of product innovation teams across their wide range of customers.

 

This agreement, with one of the UK's leading specialist ingredients suppliers, is an important step in optimising the supply chain by leveraging Knighton's purchasing power, manufacturing efficiencies and partner network to scale up the manufacture and supply of SlimBiome®.  This is an important step to meet the needs of major UK retailers and exports of SlimBiome®, and SlimBiome® containing products to Tata, and potential new partners, in the Iarge consumer markets of India and the USA.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Knighton Foods. We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome®. Their development work greatly improved SlimBiome's solubility, taste and mouthfeel whilst reducing the overall cost of manufacture. We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome® from partners worldwide."

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0883

Liam Murray

 

FinnCap (Broker)

 

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

About Knighton Foods www.knightonfoods.com

 

Knighton Foods, based in the U.K are a leading producer of high quality specialist powdered products. Their suite of processes includes, processing, blending and packaging capabilities ranging from portion controlled sachets to 1 ton bulk containers. 

Knighton's technical and R&D capabilities have been developed over 100+ years' and deliver value and functionality to ingredients and finished products, for use in the Retail, Out of Home, and Ingredients sectors. Examples of which can be found on the shelves of the UK's leading supermarkets in some of the most recognised consumer brands, and leading chains of fast food restaurants and coffee shops.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREFLFXDBFBFBX
Date   Source Headline
28th Jul 20162:30 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSCompletion of pilot launch and creation of JV
14th Jul 20167:00 amRNSNew patent filing
5th Jul 20167:00 amRNSStrategy update
4th Jul 20163:36 pmRNSHolding(s) in Company
30th Jun 20163:06 pmRNSExercise of Warrants and Issue of Equity
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
2nd Jun 201612:18 pmRNSExercise of Warrants and Issue of Equity
19th May 20167:00 amRNSNew patent filing
10th May 201612:39 pmRNSResult of AGM
20th Apr 201612:18 pmRNSExercise of Warrants and Issue of Equity
14th Apr 20167:00 amRNSFinal Results
7th Apr 20167:00 amRNSResults of cholesterol human volunteer study
5th Apr 20167:00 amRNSJoint development agreement signed with Royal DSM
24th Mar 20167:00 amRNSExercise of Warrants and Issue of Equity
23rd Mar 20167:00 amRNSNotice of Results
22nd Mar 20167:00 amRNSSecond contract signed for Sweetbiotix
17th Mar 20167:00 amRNSJV agreement with the University of Manchester
26th Feb 201610:57 amRNSExercise of Warrants and Issue of Equity
19th Feb 201610:12 amRNSExercise of Warrants and Issue of Equity
12th Feb 20169:49 amRNSExercise of Warrants and Issue of Equity
5th Feb 20167:00 amRNSPlacing
28th Jan 201612:51 pmRNSInvestor presentation - change of venue
26th Jan 20167:00 amRNSExercise of Warrants and Issue of Equity
20th Jan 20167:00 amRNSInvestor presentation
19th Jan 20167:00 amRNSScientific Advisory Group appointment
13th Jan 20167:00 amRNSCommercial agreement signed with KSF Acquisition
21st Dec 20157:00 amRNSCompletion of Placing, Total Voting Rights
11th Dec 20151:30 pmRNSCorrection: Exercise of Warrants & Issue of Equity
11th Dec 201511:30 amRNSExercise of Warrants and Issue of Equity
7th Dec 20157:00 amRNSPlacing and Directors' Dealings
24th Nov 20157:00 amRNSDirectorate Change
20th Nov 20157:00 amRNSDevelopment agreement signed with CSL
16th Nov 201510:49 amRNSExercise of Warrants and Issue of Equity
5th Nov 20154:40 pmRNSSecond Price Monitoring Extn
5th Nov 20154:35 pmRNSPrice Monitoring Extension
3rd Nov 20157:00 amRNSNew patent filings
7th Oct 201512:30 pmRNSHolding(s) in Company
7th Oct 20157:00 amRNSNew microbial strain registrations
29th Sep 20157:00 amRNSCompletion of human studies
18th Sep 20154:18 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20157:00 amRNSHalf Yearly Report
11th Aug 201512:08 pmRNSResult of AGM
28th Jul 20157:00 amRNSCompletion of human studies
9th Jul 20157:00 amRNSContract signed with Instituto de Química Orgánica
23rd Jun 20155:00 pmRNSHolding(s) in Company
17th Jun 20154:59 pmRNSExercise of Warrants and Issue of Equity
12th Jun 20152:05 pmRNSHolding(s) in Company
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.